0000899243-21-034312.txt : 20210826 0000899243-21-034312.hdr.sgml : 20210826 20210826191516 ACCESSION NUMBER: 0000899243-21-034312 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210818 FILED AS OF DATE: 20210826 DATE AS OF CHANGE: 20210826 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Michaelson Jennifer CENTRAL INDEX KEY: 0001838061 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 211213743 MAIL ADDRESS: STREET 1: C/O CULLINAN MANAGEMENT, INC. STREET 2: ONE MAIN STREET SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Oncology, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-08-18 2021-08-24 0 0001789972 Cullinan Oncology, Inc. CGEM 0001838061 Michaelson Jennifer C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 520 CAMBRIDGE MA 02142 0 1 0 0 See Remarks Common Stock 2021-08-18 4 M 0 4000 4.30 A 26911 D Common Stock 2021-08-18 4 S 0 2863 27.50 D 24048 D Common Stock 2021-08-18 4 S 0 1137 28.07 D 22911 D Stock Option (Right to Buy) 4.30 2021-08-18 4 M 0 4000 0.00 D 2030-10-28 Common Stock 4000 225978 D Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Chief Development Officer, Biologics This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021. /s/ Jeffrey Trigilio, Attorney-in-Fact 2021-08-26